Quantifying natural amyloid plaque accumulation using disease progression modeling with ADNI, BioFINDER, and LEARN datasets
This natural amyloid plaque model predicting the time course over decades may be used in designing and interpreting novel AD trials. Preventing amyloid accumulation would avoid the onset of preclinical AD, downstream irreversible pathological changes, and ultimately cognitive and functional impairment due to AD.
Authors
- Yvonne R. Vandenburg
- Ivelina Gueorguieva (ORCID: https://orcid.org/0000-0001-5864-8924)
- Sergey Shcherbinin
- Kevin Biglan (ORCID: https://orcid.org/0000-0001-5114-3755)
- Matan C. Dabora
- T. Wang
- Ilke Tunali
- Samantha C. Burnham (ORCID: https://orcid.org/0000-0003-4805-5193)
- Kay Hoong Chow
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (United Kingdom) (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103495
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00